Edison Highlights Strong FY26 Performance for Worldwide Healthcare Trust

Edison Investment Research has released a report on Worldwide Healthcare Trust (WWH), noting significant outperformance for the fiscal year 2026. The Trust recorded a net asset value (NAV) and share price total returns of 10.0% and 13.1%, respectively, surpassing the benchmark's 1.8% return. This recovery follows a challenging FY25, amid US drug pricing and tariff uncertainties affecting healthcare stocks.

WWH co-managers Sven Borho and Trevor Polischuk credit the turnaround to a consistent focus on innovation and growth. The Biotech M&A Basket returned 55.9% in sterling, contributing 5.6 percentage points to the total returns. Since its inception in April 1995, WWH has achieved average annual NAV total returns of 13.3%, compared to the benchmark's 11.0%.

The team expects the improved US policy clarity, favorable biotech valuations, and the looming patent cliff for large pharmaceutical companies to drive continued merger and acquisition activity.